Aging Limits Glia-Based Neuron Regeneration in Mouse Retina, Study Finds

Aging substantially reduced the ability of support cells in the mouse retina to generate replacement neurons, according to a study from SUNY Upstate Medical University published in the Proceedings of the National Academy of Sciences.

The research examined whether glial reprogramming—a strategy that converts retinal support cells into neurons—remains possible in aged tissue. Earlier work had shown that the approach can produce new retinal neurons in young mice, but the study’s authors said the effects of aging had received far less attention despite the close relationship between neurodegenerative disease and aging.

Using multiple strategies based on transcription factors, the researchers found that glia from older retinas were much less efficient at becoming neurons than glia in younger animals. The work was led by Levi Todd’s laboratory, with Jugasmita Deka and other graduate neuroscience researchers listed as authors.

The researchers pointed to two potential contributors. Cells in the nervous system, including neurons and glia, generally remain in place for life rather than being routinely replaced. Over time, the study team said, those cells may lose some of the flexibility seen in younger tissue. The researchers also highlighted age-related inflammation, sometimes called “inflammaging,” as a potentially more targetable barrier.

According to the report, aging can weaken the barrier that normally limits immune-system activity in the brain and retina. Increased immune activity and inflammation may then interfere with the cellular changes required for regeneration. In the experiments, anti-inflammatory steroids partially restored the regenerative response in aged retinal tissue.

That result does not show that steroids can restore vision or regenerate retinal neurons in humans. The research was conducted in mice, and the partial response suggests that broad suppression of inflammation may not be sufficient on its own. The investigators said their next goal is to identify the specific molecules and biological pathways involved, potentially allowing future research into more targeted approaches such as antibodies directed at individual inflammatory pathways.

The study is notable because it tested a regeneration strategy in aged nervous-system tissue rather than focusing only on young animals. However, it does not establish that glial reprogramming is effective in people, nor that it can treat glaucoma, Alzheimer’s disease, Parkinson’s disease, or other age-related neurodegenerative disorders. It instead identifies aging-related limits that would need to be addressed before the approach could be evaluated as a human therapy.